logo-loader
viewVolitionRx

VolitionRx to present at Canaccord Genuity MedTech event

VolitionRx Limited will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016 being held on November 17 in New York

rsz_shutterstock_181358063.jpg
VolitionRx presenting at New York event

VolitionRx Limited (NYSEMKT:VNRX) will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016 being held on November 17 in New York.

Cameron Reynolds, Chief Executive Officer of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the company's recently announced product launch of its Nu.QTM Colorectal Cancer Screening Triage Test.

Quick facts: VolitionRx

Price: 3.46 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $159.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRX progressing towards launch of first commercial products using...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive the firm rounded out the second quarter with $21.3 million in cash and equivalents compared to $12 million in the same quarter a year ago. The company's now tested two independent cohorts of COVID-19 positive patients with...

1 day, 3 hours ago

2 min read